Fraunhofer IAF has developed a monolithic bidirectional switch with a blocking voltage of 1200 V using its GaN-on-insulator ...

At the upcoming PCIM Conference (6th - 8th May, Nuremberg, Germany) Fraunhofer IAF will present a paper on a novel GaN ...

The poster presentations will include preclinical safety and efficacy results, highlighting STRO-004's significant anti-tumor activity and safety profile. Sutro's CEO, Jane Chung, expressed ...

Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy ...

SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...

today announced that the company will present three posters related to both of its pipeline programs at the American Thoracic Society (ATS) 2025 International Conference (ATS 2025). ATS 2025 is ...

including two oral presentations, at the upcoming 28 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 13-17, 2025, in New Orleans, Louisiana. "We ...

today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City ...

These posters highlight key data supporting the ... Chairman and Chief Executive Officer of Nuvectis commented,“This year's AACR presentations mark an important milestone in the development ...

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...